PDF(Pubmed)
Abstract：
The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.
摘要：
医学上重要的真菌名称更改的快速步伐给参与患者护理的临床实验室和临床医生带来了挑战。我们描述了名称更改的两个来源，它们具有不同的驱动因素，在物种和属的水平。这里提出了一些建议，以减少名称更改的数量。我们敦促分类学家提供分类新颖性的诊断标记。鉴于系统发育树由于可变分类单元采样而不稳定，我们主张保持属在最大可能的大小。复合物或系列中已识别物种的报告应尽可能包括总体物种的名称和分子同胞的名称，通常是神秘的物种。因为对同一物种使用不同的名称在未来许多年是不可避免的，所有医学上重要的真菌名称的开放式在线数据库，具有适当的名称名称和同义词，是必不可少的。我们进一步建议，虽然分类学发现仍在继续，临床实验室和临床医生对新名称更改的适应，由常设委员会进行常规审查，以便随着时间的推移进行验证和稳定性，参考开放访问数据库，其中更改的原因以透明的方式列出。
